

# Riccardo Cappato

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10589899/publications.pdf>

Version: 2024-02-01

78  
papers

19,837  
citations

136950

32  
h-index

79698

73  
g-index

82  
all docs

82  
docs citations

82  
times ranked

9260  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term results of first-generation S-ICD systems: strong from the start and through the threats of time. <i>European Heart Journal</i> , 2022, 43, 2051-2053.	2.2	2
2	Management of atrial fibrillation: two decades of progress – a scientific statement from the European Cardiac Arrhythmia Society. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 65, 287-326.	1.3	20
3	Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. <i>Europace</i> , 2021, 23, 65-72.	1.7	2
4	Surveys and Registries on Catheter Ablation of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008073.	4.8	6
5	Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VerT trial. <i>Europace</i> , 2021, 23, 1539-1547.	1.7	1
6	How effective is cryoablation in the treatment of atrial fibrillation?. <i>European Heart Journal Supplements</i> , 2021, 23, E51-E54.	0.1	4
7	Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. <i>BMJ, The</i> , 2021, 375, e066450.	6.0	6
8	Stroke and mortality risk after atrial fibrillation ablation: lesson from the CABANA trial. <i>European Heart Journal Supplements</i> , 2020, 22, L38-L40.	0.1	0
9	Catheter Ablation of Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 646-648.	3.2	0
10	Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VerT Trial. <i>TH Open</i> , 2020, 04, e20-e32.	1.4	29
11	The subcutaneous implantable cardioverter-defibrillator: Current trends in clinical practice between guidelines and technology progress. <i>European Journal of Internal Medicine</i> , 2019, 65, 6-11.	2.2	3
12	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <i>European Heart Journal</i> , 2019, 40, 3013-3021.	2.2	125
13	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1261.	7.4	953
14	Complications of catheter ablation: incidence, diagnosis and clinical management. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2019, 30, 363-370.	0.8	2
15	Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.. <i>Clinical Cardiology</i> , 2018, 41, 440-449.	1.8	12
16	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Europace</i> , 2018, 20, e1-e160.	1.7	767
17	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. <i>Europace</i> , 2018, 20, 157-208.	1.7	375
18	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. <i>Heart Rhythm</i> , 2017, 14, e275-e444.	0.7	1,671

#	ARTICLE	IF	CITATIONS
19	Pulmonary Vein Stenosis Following Radiofrequency Ablation of Atrial Fibrillation. JACC: Clinical Electrophysiology, 2017, 3, 599-601.	3.2	2
20	Sudden cardiac death: New approaches for implantable cardioverter-defibrillators (ICDs). International Journal of Cardiology, 2017, 237, 38-41.	1.7	4
21	The Year in Cardiology 2016: arrhythmias and cardiac implantable electronic devices. European Heart Journal, 2017, 38, ehv629.	2.2	1
22	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Journal of Arrhythmia, 2017, 33, 369-409.	1.2	348
23	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Journal of Interventional Cardiac Electrophysiology, 2017, 50, 1-55.	1.3	83
24	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Heart Rhythm, 2017, 14, e445-e494.	0.7	135
25	Entirely subcutaneous defibrillator and complex congenital heart disease: Data on long-term clinical follow-up. World Journal of Cardiology, 2017, 9, 547.	1.5	14
26	Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban. Thrombosis and Haemostasis, 2016, 116, S2-S12.	3.4	7
27	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. American Journal of Medicine, 2016, 129, 1117-1123.e2.	1.5	14
28	Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VERT trial. Europace, 2016, 18, 184-190.	1.7	28
29	Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace, 2016, 18, euv408.	1.7	21
30	Catheter ablation in atrial fibrillation: a state-of-the-art review. Research Reports in Clinical Cardiology, 2015, , 153.	0.2	1
31	Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator Among Older Patients. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 179-186.	2.2	90
32	Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. European Heart Journal, 2015, 36, 1805-1811.	2.2	370
33	Longevity of the Subcutaneous Implantable Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1159-1163.	4.8	37
34	The Entirely Subcutaneous Defibrillator – A New Generation and Future Expectations. Arrhythmia and Electrophysiology Review, 2015, 04, 116.	2.4	14
35	Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTtrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion. American Heart Journal, 2014, 167, 646-652.	2.7	25
36	Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European Heart Journal, 2014, 35, 3346-3355.	2.2	329

#	ARTICLE	IF	CITATIONS
37	Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2014, 41, 107-116.	1.3	16
38	Prospective European Survey on Atrial Fibrillation Ablation: Clinical Characteristics of Patients and Ablation Strategies Used in Different Countries. Journal of Cardiovascular Electrophysiology, 2014, 25, 1074-1081.	1.7	22
39	Ebstein's Anomaly and Arrhythmia Management. , 2014, , 73-82.		0
40	Feasibility of Defibrillation and Automatic Arrhythmia Detection Using an Exclusively Subcutaneous Defibrillator System in Canines. Journal of Cardiovascular Electrophysiology, 2013, 24, 77-82.	1.7	11
41	Shock efficacy of the entirely subcutaneous defibrillator for termination of spontaneous ventricular fibrillation in Brugada syndrome. Heart Rhythm, 2013, 10, 1807-1809.	0.7	12
42	Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. Heart Rhythm, 2013, 10, 828-835.	0.7	13
43	Silent Cerebral Embolism and New Technologies for Catheter Ablation of Atrial Fibrillation: Time to Take a Deep Breath. Journal of Cardiovascular Electrophysiology, 2013, 24, 22-23.	1.7	6
44	Ablation of paroxysmal and persistent atrial fibrillation with multielectrode phased radiofrequency duty-cycled catheters. Journal of Cardiovascular Medicine, 2013, 14, 879-885.	1.5	10
45	Venice Chart International Consensus Document on Atrial Fibrillation Ablation: 2011 Update. Journal of Cardiovascular Electrophysiology, 2012, 23, 890-923.	1.7	79
46	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the E. Europace, 2012, 14, 528-606.	1.7	1,497
47	Subcutaneous chronic implantable defibrillation systems in humans. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 325-332.	1.3	19
48	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.	0.7	1,541
49	2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Journal of Interventional Cardiac Electrophysiology, 2012, 33, 171-257.	1.3	1,167
50	Development of an Entirely Subcutaneous Implantable Cardioverter-Defibrillator. Progress in Cardiovascular Diseases, 2012, 54, 493-497.	3.1	9
51	Late Arrhythmias: Current Approaches. , 2012, , 167-178.		0
52	Delayed Cardiac Tamponade After Radiofrequency Catheter Ablation of Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 2696-2697.	2.8	78
53	Venice Chart International Consensus Document on Ventricular Tachycardia/Ventricular Fibrillation Ablation. Journal of Cardiovascular Electrophysiology, 2010, 21, 339-379.	1.7	97
54	An Entirely Subcutaneous Implantable Cardioverter-Defibrillator. New England Journal of Medicine, 2010, 363, 36-44.	27.0	686

#	ARTICLE	IF	CITATIONS
55	Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2010, 3, 32-38.	4.8	1,962
56	NICE guidance on catheter ablation of atrial fibrillation using an epicardial (non-thorascopic) approach. <i>Heart</i> , 2009, 95, 1956-1957.	2.9	2
57	Current state of knowledge and experts' perspective on the subcutaneous implantable cardioverter-defibrillator. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009, 25, 83-88.	1.3	16
58	Searching for Left Atrial Thrombi Prior to Catheter Ablation of Atrial Fibrillation: Are There Patients Who Can Safely Avoid Preablation Transesophageal Echocardiography?. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 385-387.	1.7	2
59	Arrhythmia Detection in Single- and Dual-Chamber Implantable Cardioverter Defibrillators: The More Leads, the Better?. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 1077-1082.	1.7	26
60	Prevalence and Causes of Fatal Outcome in Catheter Ablation of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1798-1803.	2.8	537
61	An unusual case of permanent junctional reciprocating tachycardia: Successful ablation at the mitral annulus-aorta junction. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2008, 23, 213-217.	1.3	11
62	Radiofrequency Catheter Ablation of Atrial Fibrillation in Athletes Referred for Disabling Symptoms Preventing Usual Training Schedule and Sport Competition. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 457-462.	1.7	96
63	HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation Developed in partnership with the European Heart Rhythm Association (EHRA) and the European Cardiac Arrhythmia Society (ECAS); in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), and the Soci. <i>Europace</i> , 2007, 9, 335-379.	1.7	741
64	HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up. <i>Heart Rhythm</i> , 2007, 4, 816-861.	0.7	1,258
65	Trans-Septal Catheterization in the Electrophysiology Laboratory. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1037-1042.	2.8	182
66	Regression of warfarin-resistant left atrial appendage thrombus after ablation of atrial fibrillation and permanent pacing. <i>Journal of Cardiovascular Medicine</i> , 2006, 7, 628-630.	1.5	0
67	Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation. <i>Circulation</i> , 2005, 111, 1100-1105.	1.6	1,351
68	Towards more effective techniques for catheter ablation of atrial fibrillation: to aim for electrical disconnection of pulmonary veins or not?. <i>European Heart Journal</i> , 2005, 26, 627-630.	2.2	11
69	Towards a unified strategy for atrial fibrillation ablation?: reply. <i>European Heart Journal</i> , 2005, 26, 1688-1688.	2.2	0
70	Response to programmed ventricular stimulation and clinical outcome in cardiac arrest survivors receiving randomised assignment to implantable cardioverter defibrillator or antiarrhythmic drug therapy. <i>European Heart Journal</i> , 2004, 25, 642-649.	2.2	8
71	Prospective Assessment of Late Conduction Recurrence Across Radiofrequency Lesions Producing Electrical Disconnection at the Pulmonary Vein Ostium in Patients With Atrial Fibrillation. <i>Circulation</i> , 2003, 108, 1599-1604.	1.6	387
72	Role of Implantable Cardioverter Defibrillators in Dilated Cardiomyopathy. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, S106-9.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Repetitive monomorphic ventricular tachycardia originating from the aortic sinus cusp. Journal of the American College of Cardiology, 2002, 39, 500-508.	2.8	534
74	Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest. Circulation, 2000, 102, 748-754.	1.6	1,341
75	Catheter Ablation of Paroxysmal Atrial Fibrillation Using a 3D Mapping System. Circulation, 1999, 100, 1203-1208.	1.6	327
76	Modification of the Substrate for Maintenance of Idiopathic Human Atrial Fibrillation. Circulation, 1999, 100, 2085-2092.	1.6	214
77	Programmable Polarity: Effects on Pacing and Sensing of Bipolar Steroid-Eluting Leads. PACE - Pacing and Clinical Electrophysiology, 1996, 19, 2099-2102.	1.2	4
78	ICD versus Drugs in Cardiac Arrest Survivors: Preliminary Results of the Cardiac Arrest Study Hamburg. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 552-558.	1.2	55